[
  {
    "ts": null,
    "headline": "GE HealthCare Technologies Inc. stock rises Wednesday, outperforms market",
    "summary": "GE HealthCare Technologies Inc. stock rises Wednesday, outperforms market",
    "url": "https://finnhub.io/api/news?id=f5c00ed46ccee88a0c21d30b5458e656a348913668b4a48596dff5982339a6c0",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750870500,
      "headline": "GE HealthCare Technologies Inc. stock rises Wednesday, outperforms market",
      "id": 135551822,
      "image": "",
      "related": "GEHC",
      "source": "MarketWatch",
      "summary": "GE HealthCare Technologies Inc. stock rises Wednesday, outperforms market",
      "url": "https://finnhub.io/api/news?id=f5c00ed46ccee88a0c21d30b5458e656a348913668b4a48596dff5982339a6c0"
    }
  },
  {
    "ts": null,
    "headline": "SNN vs. GEHC: Which Stock Is the Better Value Option?",
    "summary": "SNN vs. GEHC: Which Stock Is the Better Value Option?",
    "url": "https://finnhub.io/api/news?id=a135543a5c9f0e76a4a1ae5aa79159a5dc93e5178ec743d43ef08ae471bd0595",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750866002,
      "headline": "SNN vs. GEHC: Which Stock Is the Better Value Option?",
      "id": 135531394,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GEHC",
      "source": "Yahoo",
      "summary": "SNN vs. GEHC: Which Stock Is the Better Value Option?",
      "url": "https://finnhub.io/api/news?id=a135543a5c9f0e76a4a1ae5aa79159a5dc93e5178ec743d43ef08ae471bd0595"
    }
  },
  {
    "ts": null,
    "headline": "GEHC Stock Gains Post FDA's Nod for Vizamyl's Expanded Indications",
    "summary": "GE HealthCare gains FDA nod to expand Vizamyl's use, unlocking new diagnostic and therapy-monitoring capabilities.",
    "url": "https://finnhub.io/api/news?id=ede31a9c246da17fa32de62796ea2c70a5c5b41f4615f4a26505ae3fdf6f6b8b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750860180,
      "headline": "GEHC Stock Gains Post FDA's Nod for Vizamyl's Expanded Indications",
      "id": 135526675,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GEHC",
      "source": "Yahoo",
      "summary": "GE HealthCare gains FDA nod to expand Vizamyl's use, unlocking new diagnostic and therapy-monitoring capabilities.",
      "url": "https://finnhub.io/api/news?id=ede31a9c246da17fa32de62796ea2c70a5c5b41f4615f4a26505ae3fdf6f6b8b"
    }
  },
  {
    "ts": null,
    "headline": "The 5 Most Interesting Analyst Questions From GE HealthCare’s Q1 Earnings Call",
    "summary": "GE HealthCare’s first quarter results came in above Wall Street expectations, as the company delivered broad-based revenue growth across all business segments. Management credited strong U.S. demand for imaging equipment—particularly in cardiology and oncology—as well as robust order activity and backlog expansion, for the positive momentum. CEO Peter Arduini highlighted, “Record double-digit orders growth as a standalone company was driven by strength in the U.S. market, where we see customers",
    "url": "https://finnhub.io/api/news?id=841cb43066fe2c2c44f9920c0004cb9af57f14b806a97f2fe613862b04e8bcd6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750851612,
      "headline": "The 5 Most Interesting Analyst Questions From GE HealthCare’s Q1 Earnings Call",
      "id": 135554334,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GEHC",
      "source": "Yahoo",
      "summary": "GE HealthCare’s first quarter results came in above Wall Street expectations, as the company delivered broad-based revenue growth across all business segments. Management credited strong U.S. demand for imaging equipment—particularly in cardiology and oncology—as well as robust order activity and backlog expansion, for the positive momentum. CEO Peter Arduini highlighted, “Record double-digit orders growth as a standalone company was driven by strength in the U.S. market, where we see customers",
      "url": "https://finnhub.io/api/news?id=841cb43066fe2c2c44f9920c0004cb9af57f14b806a97f2fe613862b04e8bcd6"
    }
  },
  {
    "ts": null,
    "headline": "GE HealthCare: expanded indication for Vizamyl",
    "summary": "GE HealthCare announces that the FDA has approved an update to the labeling for its PET imaging agent Vizamyl , expanding its indications and authorizing quantitative analysis of exams. This change...",
    "url": "https://finnhub.io/api/news?id=024f97c54509dca8fe08e7f7d533cfa8acc16dd37ac76886cf9c2bae1b7a7d1d",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750843251,
      "headline": "GE HealthCare: expanded indication for Vizamyl",
      "id": 135524943,
      "image": "",
      "related": "GEHC",
      "source": "Finnhub",
      "summary": "GE HealthCare announces that the FDA has approved an update to the labeling for its PET imaging agent Vizamyl , expanding its indications and authorizing quantitative analysis of exams. This change...",
      "url": "https://finnhub.io/api/news?id=024f97c54509dca8fe08e7f7d533cfa8acc16dd37ac76886cf9c2bae1b7a7d1d"
    }
  }
]